A detailed history of Ameritas Investment Partners, Inc. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 17,114 shares of LYEL stock, worth $18,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,114
Previous 17,114 -0.0%
Holding current value
$18,825
Previous $24,000 4.17%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $6,000 - $13,862
4,138 Added 31.89%
17,114 $25,000
Q2 2022

Aug 12, 2022

BUY
$3.68 - $6.8 $5,416 - $10,009
1,472 Added 12.8%
12,976 $84,000
Q1 2022

May 13, 2022

BUY
$5.05 - $7.7 $48,949 - $74,636
9,693 Added 535.23%
11,504 $58,000
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $19,921 - $32,507
1,811 New
1,811 $27,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.